Cell-based therapies for myocardial repair: emerging role for bone marrow-derived mesenchymal stem cells (MSCs) in the treatment of the chronically injured heart

Methods Mol Biol. 2013;1037:145-63. doi: 10.1007/978-1-62703-505-7_8.

Abstract

Accumulating data support the use of bone marrow (BM)-derived MSCs in animal models (e.g., swine) to restore cardiac function and tissue perfusion in chronic cardiac injury. Based on results obtained in swine, we are currently conducting phase I/II clinical trials to address the safety, cell type, cell dose, delivery technique, and efficacy of MSCs in patients with chronic heart failure. MSCs for these trials are isolated from harvested BM and then processed and expanded for intracardiac injection. The BM-MSCs in use for the clinical trials are of clinical grade having been processed successfully in an FDA-approved cGMP facility.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Cell Separation
  • Cell- and Tissue-Based Therapy* / methods
  • Cell- and Tissue-Based Therapy* / standards
  • Chronic Disease
  • Cryopreservation / methods
  • Heart Diseases / therapy
  • Humans
  • Mesenchymal Stem Cell Transplantation*
  • Mesenchymal Stem Cells / cytology*
  • Primary Cell Culture
  • Swine